Immunome INC Form 4 insider transactions

Isaac Barchas, a Director of Immunome Inc., sold 83,464 shares of common stock on August 10, 2026.

Kinney Horn, CHIEF BUSINESS OFFICER of Immunome Inc., sold 90,616 shares of common stock on August 4, 2026 for $25.09 per share.

Kinney Horn, CHIEF BUSINESS OFFICER of Immunome Inc., reported multiple transactions in common stock on July 23, 2026.

Philip Tsai, Chief Technical Officer of Immunome Inc., reported multiple transactions in common stock on July 23, 2026.

Sandra G. Stoneman, CHIEF LEGAL OFFICER & GC of Immunome Inc., reported multiple transactions in common stock on July 23, 2026.

Jack Higgins, Chief Scientific Officer of Immunome Inc., reported multiple transactions in common stock on July 23, 2026.

Max Rosett, Chief Financial Officer of Immunome Inc., reported multiple transactions in common stock on July 23, 2026.

Robert Lechleider, Chief Medical Officer of Immunome Inc., reported multiple transactions in common stock on July 23, 2026.

Clay B Siegall, President and CEO and a Director of Immunome Inc., reported multiple transactions in common stock on July 23, 2026.

Immunome Inc. Chief Business Officer Kinney Horn sold 1,092 shares of common stock for $25 per share, totaling $27,300, as part of a pre-arranged 10b5-1 trading plan.

Immunome Inc. Director Isaac Barchas reported the sale of common stock through a pre-arranged trading plan, with transactions occurring on July 6th and 7th, 2026.

Immunome Inc. Chief Medical Officer Robert Lechleider reported transactions involving the sale of common stock and the acquisition of stock options.

Immunome Inc. Director Isaac Barchas reported the sale of common stock totaling 200,000 shares through Rule 10b5-1 trading plans, with transactions occurring on June 30 and July 2, 2026.

Immunome Inc. Chief Medical Officer Robert Lechleider reported transactions involving the sale of company stock, executed under a pre-arranged trading plan.

Immunome CFO Max Rosett exercised 60,000 stock options and subsequently sold the shares under a Rule 10b5-1 trading plan.

Director Sandra M. Swain was granted 9,897 stock options in Immunome, Inc. as part of standard equity compensation.

Director Philip Wagenheim was granted 9,897 stock options in Immunome, Inc. as part of standard equity compensation.

Immunome, Inc. director Jean-Jacques Bienaime was granted 9,897 stock options as part of his compensation package.

Director James P. Boylan was granted 9,897 stock options in Immunome, Inc. to be held for the benefit of Enavate Sciences, LP.

Director Isaac Barchas was granted 9,897 stock options in Immunome, Inc. to be held for the benefit of Arsenal Bridge Ventures.

Director Carol Schafer was granted 9,897 stock options in Immunome, Inc. as part of a standard equity compensation plan.

Director Jean-Jacques Bienaime disclosed a series of short-swing common stock transactions in Immunome, Inc. on June 5, 2026.

Director Jean-Jacques Bienaime acquired 5,000 shares of Immunome Inc. common stock for an average price of $20.70 per share.

Immunome Inc. Chief Scientific Officer Jack Higgins sold 9,438 shares of common stock for $21.64 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Immunome Inc. Chief Financial Officer Max Rosett reported transactions involving company common stock and stock options on April 2, 2026, executed under a Rule 10b5-1 trading plan.

Immunome Inc.'s Chief Scientific Officer, Jack Higgins, reported a gift of 6,291 common shares, adjusting his direct beneficial ownership.

Immunome Inc.'s President and CEO, Clay B. Siegall, acquired 25,450 shares of common stock for approximately $500,000, increasing his direct beneficial ownership.

Immunome Inc. Director and 10% owner Philip Wagenheim sold a total of 65,000 shares of common stock for approximately $1.3 million across two pre-scheduled transactions in March 2026.

Immunome Inc. Director Jean Jacques Bienaime acquired 2,000 shares of common stock through pre-planned transactions, increasing his direct ownership.

Immunome Inc.'s President and CEO, Clay B. Siegall, acquired 4,729 shares of common stock at $21.15 per share through a pre-arranged trading plan.